Skip to main content
Premium Trial:

Request an Annual Quote

Bit More Diverse, But More to Do

Cancer clinical trials have become more diverse, though some populations are still underrepresented, US News & World Report says.

A University of California, San Diego-led team of researchers examined the representation of minorities, women, and the elderly in clinical trials funded by the US National Cancer Institute. By delving through the NCI Clinical Data Update System, the researchers examined the demographics of 242,720 participants in clinical trials of breast, colorectal, lung, and prostate cancer between 2000 and 2019. As they report in the journal Cancer, they found Black patients were more likely to participate in breast, lung, and prostate cancer trials and Hispanic patients were more likely to participate in breast, colorectal, lung, and prostate cancer trials in 2015 through 2019, as compared to 2000 to 2004.

However, the researchers note that Black and Hispanic patients remain underrepresented in trials. "Our article indicates that the disparity for clinical enrollment in NCI clinical trials has narrowed for minorities, but further efforts are still needed," first author Juan Javier-DesLoges from UC San Diego Health says in a statement.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.